| Outcome Measures: |
Primary: Number of Participants Experiencing Adverse Events (AEs) On Study, An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience., From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks)|Number of Participants Who Discontinued Treatment Due to an AE, An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience., From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks) | Secondary: Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006, The AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity., From pre-dose to 168 hours post-dose|Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose, From pre-dose to 168 hours post-dose|Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose, From pre-dose to 168 hours post-dose|Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose, The apparent terminal half-life was defined as the time required for the plasma concentration of MK1006 to decrease 50% in the final stage of its elimination, From pre-dose to 168 hours post-dose|Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006, The AUC(0-24) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose., From pre-dose to 168 hours post-dose
|
